271 related articles for article (PubMed ID: 10990077)
1. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.
Pozzilli P; Pitocco D; Visalli N; Cavallo MG; Buzzetti R; Crinò A; Spera S; Suraci C; Multari G; Cervoni M; Manca Bitti ML; Matteoli MC; Marietti G; Ferrazzoli F; Cassone Faldetta MR; Giordano C; Sbriglia M; Sarugeri E; Ghirlanda G
Diabetologia; 2000 Aug; 43(8):1000-4. PubMed ID: 10990077
[TBL] [Abstract][Full Text] [Related]
2. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
Pozzilli P; Visalli N; Signore A; Baroni MG; Buzzetti R; Cavallo MG; Boccuni ML; Fava D; Gragnoli C; Andreani D
Diabetologia; 1995 Jul; 38(7):848-52. PubMed ID: 7556988
[TBL] [Abstract][Full Text] [Related]
3. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.
Chaillous L; Lefèvre H; Thivolet C; Boitard C; Lahlou N; Atlan-Gepner C; Bouhanick B; Mogenet A; Nicolino M; Carel JC; Lecomte P; Maréchaud R; Bougnères P; Charbonnel B; Saï P
Lancet; 2000 Aug; 356(9229):545-9. PubMed ID: 10950231
[TBL] [Abstract][Full Text] [Related]
4. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study).
Pozzilli P; Visalli N; Cavallo MG; Signore A; Baroni MG; Buzzetti R; Fioriti E; Mesturino C; Fiori R; Romiti A; Giovannini C; Lucentini L; Matteoli MC; Crinò A; Teodonio C; Paci F; Amoretti R; Pisano L; Suraci C; Multari G; Suppa M; Sulli N; De Mattia G; Faldetta MR
Eur J Endocrinol; 1997 Sep; 137(3):234-9. PubMed ID: 9330586
[TBL] [Abstract][Full Text] [Related]
5. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395
[TBL] [Abstract][Full Text] [Related]
6. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
Schloot NC; Meierhoff G; Lengyel C; Vándorfi G; Takács J; Pánczél P; Barkai L; Madácsy L; Oroszlán T; Kovács P; Sütö G; Battelino T; Hosszufalusi N; Jermendy G
Diabetes Metab Res Rev; 2007 May; 23(4):276-85. PubMed ID: 17103487
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).
Crinò A; Schiaffini R; Manfrini S; Mesturino C; Visalli N; Beretta Anguissola G; Suraci C; Pitocco D; Spera S; Corbi S; Matteoli MC; Patera IP; Manca Bitti ML; Bizzarri C; Pozzilli P;
Eur J Endocrinol; 2004 May; 150(5):719-24. PubMed ID: 15132730
[TBL] [Abstract][Full Text] [Related]
8. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial.
Coutant R; Landais P; Rosilio M; Johnsen C; Lahlou N; Chatelain P; Carel JC; Ludvigsson J; Boitard C; Bougnères PF
Diabetologia; 1998 Sep; 41(9):1040-6. PubMed ID: 9754822
[TBL] [Abstract][Full Text] [Related]
9. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
[TBL] [Abstract][Full Text] [Related]
10. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study.
Allen HF; Klingensmith GJ; Jensen P; Simoes E; Hayward A; Chase HP
Diabetes Care; 1999 Oct; 22(10):1703-7. PubMed ID: 10526739
[TBL] [Abstract][Full Text] [Related]
11. A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8).
Pozzilli P; Crinò A; Schiaffini R; Manfrini S; Fioriti E; Coppolino G; Pitocco D; Visalli N; Corbi S; Spera S; Suraci C; Cervoni M; Matteoli MC; Patera IP; Ghirlanda G;
Diabetes Technol Ther; 2003; 5(6):965-74. PubMed ID: 14709198
[TBL] [Abstract][Full Text] [Related]
12. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
[TBL] [Abstract][Full Text] [Related]
13. Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study.
Pozzilli P; Visalli N; Boccuni ML; Baroni MG; Buzzetti R; Fioriti E; Signore A; Cavallo MG; Andreani D; Lucentini L
Diabetes Care; 1994 Aug; 17(8):897-900. PubMed ID: 7956639
[TBL] [Abstract][Full Text] [Related]
14. Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes.
Couper JJ; Hudson I; Werther GA; Warne GL; Court JM; Harrison LC
Diabetes Res Clin Pract; 1991 Jan; 11(1):9-16. PubMed ID: 2019237
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group.
Pozzilli P; Visalli N; Boccuni ML; Baroni MG; Buzzetti R; Fioriti E; Signore A; Cavallo MG; Andreani D; Lucentini L
Diabet Med; 1994; 11(1):98-104. PubMed ID: 8181261
[TBL] [Abstract][Full Text] [Related]
16. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group.
J Clin Endocrinol Metab; 1987 Jul; 65(1):30-6. PubMed ID: 2884229
[TBL] [Abstract][Full Text] [Related]
17. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
Raz I; Elias D; Avron A; Tamir M; Metzger M; Cohen IR
Lancet; 2001 Nov; 358(9295):1749-53. PubMed ID: 11734230
[TBL] [Abstract][Full Text] [Related]
18. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI).
Visalli N; Cavallo MG; Signore A; Baroni MG; Buzzetti R; Fioriti E; Mesturino C; Fiori R; Lucentini L; Matteoli MC; Crinò A; Corbi S; Spera S; Teodonio C; Paci F; Amoretti R; Pisano L; Suraci C; Multari G; Sulli N; Cervoni M; De Mattia G; Faldetta MR; Boscherini B; Pozzilli P
Diabetes Metab Res Rev; 1999; 15(3):181-5. PubMed ID: 10441040
[TBL] [Abstract][Full Text] [Related]
19. Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients.
Vague P; Picq R; Bernal M; Lassmann-Vague V; Vialettes B
Diabetologia; 1989 May; 32(5):316-21. PubMed ID: 2526769
[TBL] [Abstract][Full Text] [Related]
20. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus.
Chase HP; Butler-Simon N; Garg S; McDuffie M; Hoops SL; O'Brien D
Diabetologia; 1990 Jul; 33(7):444-6. PubMed ID: 2144835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
